Xu Mengyue, Li Na, Liu Yan, Chen Yaru, Xie Shuping, Wang Jianfeng
Department of Ophthalmology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, 233004, China.
Department of Ophthalmology, Anhui Aier Eye Hospital, Hefei, Anhui, 230022, China.
BMC Ophthalmol. 2025 Jan 20;25(1):31. doi: 10.1186/s12886-025-03872-9.
OBJECTIVES: To evaluate the effects of short-acting cycloplegic agents, tropicamide and compound tropicamide, on ocular biological parameters and choroid thickness. METHODS: In this study, seventy pediatric subjects aged 6 to 13 years were randomly assigned to two groups: the tropicamide group and compound tropicamide group. Ocular biological parameters and choroidal thickness (CT) and subfoveal choroid thickness (SFCT) were measured in both groups and were retested 40 min after drug administration. The tropicamide eye drops were administered into the conjunctival sac every 5 min with 1 drop, for a total of 4 doses. Compound tropicamide was administered in the same way as tropicamide. Ocular biological parameters included refraction (spherical equivalent, SE), intraocular pressure (IOP), axial length (AL), anterior chamber depth (ACD), lens thickness (LT), central corneal thickness (CCT), and white to white (WTW). The CT is the regional inferior choroidal thickness of nine sectors centered on the macular fovea and automatically generated using an ETDRS grid. And the SFCT is the choroidal thickness at the subfoveal point of the macular region. RESULTS: After application of tropicamide and compound tropicamide to induce the ciliary muscle paralysis, SE, AL, and LT decreased, while ACD, CCT, and WTW increased compared to baseline(all P values < 0.05). There was no significant change in IOP before and after cycloplegia (p > 0.05). The CT in the nasal quadrant before and after ciliary paralysis was significantly thinner than other areas, the CT in the temporal quadrant was significantly thicker than others, and the CT in the inner quadrant was higher than the CT in the outer quadrant. In the tropicamide group: CT was significantly increased in the remaining quadrants except the inner inferior(I) and outer superior(S) quadrants (p < 0.05), and SFCT was also significantly increased (p = 0.005). In the compound tropicamide group: there is a significant increase in CT outer superior(S) quadrant CT (p = 0.043). Increase in the mean values of CT and SFCT in the remaining quadrants was also observed, but the difference was not statistically significant (p > 0.05). Additionally, AL and SFCT were negatively correlated. CONCLUSIONS: Some ocular biological parameters were altered after application of short-acting cycloplegic agent tropicamide and compound tropicamide to paralyze the ciliary muscle. Compared with compound tropicamide, tropicamide eye drops can reduce axial length while increasing choroid thickness.
目的:评估短效睫状肌麻痹剂托吡卡胺和复方托吡卡胺对眼部生物学参数及脉络膜厚度的影响。 方法:本研究中,70名6至13岁的儿科受试者被随机分为两组:托吡卡胺组和复方托吡卡胺组。两组均测量眼部生物学参数、脉络膜厚度(CT)和黄斑中心凹下脉络膜厚度(SFCT),并在给药后40分钟重新测量。托吡卡胺滴眼液每隔5分钟滴入结膜囊1滴,共滴4次。复方托吡卡胺的给药方式与托吡卡胺相同。眼部生物学参数包括屈光(等效球镜度,SE)、眼压(IOP)、眼轴长度(AL)、前房深度(ACD)、晶状体厚度(LT)、中央角膜厚度(CCT)和角膜横径(WTW)。CT是指以黄斑中心凹为中心的九个扇形区域的脉络膜厚度,使用ETDRS网格自动生成。SFCT是黄斑区域中心凹下点的脉络膜厚度。 结果:应用托吡卡胺和复方托吡卡胺使睫状肌麻痹后,与基线相比,SE、AL和LT降低,而ACD、CCT和WTW增加(所有P值<0.05)。睫状肌麻痹前后眼压无显著变化(p>0.05)。睫状肌麻痹前后鼻侧象限的CT明显比其他区域薄,颞侧象限的CT明显比其他区域厚,内象限的CT高于外象限。在托吡卡胺组:除内下(I)和外上(S)象限外,其余象限的CT显著增加(p<0.05),SFCT也显著增加(p=0.005)。在复方托吡卡胺组:外上(S)象限的CT显著增加(p=0.043)。其余象限的CT和SFCT平均值也有增加,但差异无统计学意义(p>0.05)。此外,AL与SFCT呈负相关。 结论:应用短效睫状肌麻痹剂托吡卡胺和复方托吡卡胺使睫状肌麻痹后,一些眼部生物学参数发生改变。与复方托吡卡胺相比,托吡卡胺滴眼液可缩短眼轴长度,同时增加脉络膜厚度。
Cochrane Database Syst Rev. 2017-2-23
Cochrane Database Syst Rev. 2025-6-11
Cochrane Database Syst Rev. 2017-12-22
Cochrane Database Syst Rev. 2018-2-6
Cochrane Database Syst Rev. 2021-4-19
Cochrane Database Syst Rev. 2005-7-20
Cochrane Database Syst Rev. 2023-2-16
Cochrane Database Syst Rev. 2018-5-22
Cochrane Database Syst Rev. 2018-7-9
Ophthalmic Physiol Opt. 2024-3
Photodiagnosis Photodyn Ther. 2023-6
J Ophthalmol. 2023-1-16
Invest Ophthalmol Vis Sci. 2022-11-1
Ophthalmic Physiol Opt. 2022-11
Invest Ophthalmol Vis Sci. 2021-7-1
Taiwan J Ophthalmol. 2019-2-20
Surv Ophthalmol. 2021